Moderna, Inc. (MRNA) is a Healthcare stock trading at $130.20 (as of 2026-08-20), with a market capitalization of $51.98B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna develops and commercializes messenger RNA therapeutics and vaccines, and it generates revenue from net product sales plus grants and collaborations.
Moderna is not yet translating its current revenue mix into profitability, with deeply negative gross and operating margins, so progress toward sustainable product revenue (and how much is offset by grants and collaborations) is central to the profit model.
| Net product sales | $0.2B |
| Grant and collaboration | $0.2B |
| Other revenue | $0.0B |
Business quality (Weak): Latest quarter (2026-03-31) shows revenue of 0.4B with negative gross margin and negative operating margin, and the revenue build appears to rely on a mix of net product sales, grant and collaboration revenue, and other revenue.
| Price | $130.20 |
| Market Cap | $51.98B |
| Price / Book | 7.69 |
| Price / Sales | 23.33 |
| FCF Yield | -5.9% |
| Revenue (TTM) | $1.94B |
| Net Margin | -145.2% |
| Revenue Growth (YoY) | 2.1% |
| EPS Growth (YoY) | -7.5% |
| FCF Growth (YoY) | -38.9% |
| Altman Z-Score | 8.96 (safe) |
| Piotroski F-Score | 3/9 (weak) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | FMR LLC ($2.32B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Stéphane Bancel |
| Employees | 5,800 |
| Country | US |
| IPO Date | 2018-12-07 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.